Sanofi Acquires Principia Biopharma in $3.6 Billion DealAcquisitions, Autoimmune Diseases, Bruton's Tyrosine Kinase (BTK) Inhibitors, Business, Immune System, Multiple Sclerosis, Oncology, Pemphigus, Pemphigus Vulgaris (PV), Premarket Trading, Product Pipelines, R&D, SharesSanofi announced the acquisition of Principia Biopharma in a deal valued at about $3.68 billion as the French company continues to transform its R&D division to more heavily emphasize oncology and other lucrative programs. Read more August 17, 2020/by Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2020/08/Sanofi-Acquires-Principia-Biopharma-in-3.6-Billion-Deal-BioSpace-8-17-20.jpeg 350 625 Andrew Humphreys https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Andrew Humphreys2020-08-17 12:30:222020-08-17 13:01:49Sanofi Acquires Principia Biopharma in $3.6 Billion Deal